Belief BioMed Congratulates AskBio for FDA Acceptance
Belief BioMed Inc. (BBM) is thrilled to announce that its partner, AskBio Inc., has received acceptance from the U.S. Food and Drug Administration (FDA) for their Investigational New Drug (IND) application regarding AB-1009. This groundbreaking investigational gene therapy uses an adeno-associated virus (AAV) aimed at treating late-onset Pompe disease. This approval enables AskBio to advance the program to Phase 1/2 clinical trials, focusing on assessing the safety of AB-1009. The clinical trial is expected to begin soon, with the recruitment of the first patient anticipated early in the upcoming year.
Collaboration Between Belief BioMed and AskBio
This achievement is a pivotal moment in the strategic collaboration established between Belief BioMed and AskBio in late 2024. During this partnership, Belief BioMed provided a sublicense for the proprietary AAV capsid, which enhances the AB-1009 gene therapy program. The collaborative efforts significantly contributed to AskBio's success in receiving FDA acceptance for the IND application, showcasing the strength of their joint capabilities in gene therapy development.
Dr. Xiao Xiao's Vision for Collaboration
Dr. Xiao Xiao, the Co-founder and Chief Science Officer at Belief BioMed, expressed his enthusiasm regarding the IND acceptance. He stated, "We are delighted to learn that our partner AskBio has received IND acceptance for its gene therapy. This milestone not only highlights our collaboration but also signals a great achievement in global gene therapy innovation. We look forward to continuing our joint efforts to expedite the development of innovative therapies worldwide. Our synergy has proven effective, and we are excited about what lies ahead."
Understanding Pompe Disease
Pompe disease is a serious inherited disorder caused by the deficiency of the enzyme acid alpha-glucosidase (GAA). This deficiency leads to harmful levels of glycogen accumulation in various cells, subsequently causing severe muscle weakness, respiratory challenges, and long-term complications. Symptoms manifest differently depending on the form of the disease, ranging from infantile versions that can be rapidly fatal, to later-onset types primarily affecting skeletal muscles. The condition is known to affect between 5,000 and 10,000 individuals globally.
Innovative Approaches to Treatment
Belief BioMed is at the forefront of developing advanced therapeutic options for genetic disorders like Pompe disease. Their commitment to pioneering research and applying state-of-the-art vector technologies positions them uniquely in the healthcare landscape. Their extensive capabilities in developing various AAV capsids showcase their determination to tailor solutions targeting different tissues effectively.
About Belief BioMed
Belief BioMed Inc. (BBM) is a global leader in biotechnology, focusing on the research, manufacturing, and clinical application of gene therapies. The company strives to provide safer and more effective treatments for severe genetic conditions by leveraging innovative viral vector technologies. Their portfolio includes numerous vector technologies and an established production platform for gene therapy products. By continuously expanding its R&D pipeline, Belief BioMed addresses significant unmet clinical needs across many therapeutic areas, including hemophilia and other chronic diseases. The recent approval of a gene therapy for adults with hemophilia B by the NMPA in China marks a significant milestone in their production endeavors.
Frequently Asked Questions
What is the significance of the IND acceptance for AB-1009?
The IND acceptance allows AskBio to move forward into clinical trials, an essential step in the drug development process.
How is Belief BioMed involved in the development of AB-1009?
Belief BioMed provided significant support, including AAV capsid technology and vector production services, crucial for the IND application.
What are the expected outcomes of the clinical trial for AB-1009?
The clinical trial aims to evaluate the safety of AB-1009, potentially leading to effective treatment for patients with late-onset Pompe disease.
Why is collaboration important in biotechnology?
Collaboration fosters innovation, combining expertise from different organizations, which can accelerate the development of effective therapies.
What conditions does Belief BioMed focus on?
Belief BioMed targets severe genetic and chronic diseases, developing therapies aimed at addressing substantial clinical needs.
